Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director | September 28, 2026 | September 30, 2026 |
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Director | December 28, 2022 | December 30, 2022 |
| OmniAb, Inc.OABI · Entity 5294 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date September 28, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,254 |
Ending reported balance
After 2026-09-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-28 · Exercise / conversion · Acquired 15,940 · Balance 82,816 Row 2 · 2026-09-28 · Tax withholding · Disposed 5,562 · Balance 77,254 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.30 · Expires 2026-10-26 | Direct | 0 |
Reported balance
After 2026-09-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-28 · Exercise / conversion · Disposed 15,940 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2027-10-26 | Direct | 12,500 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 12,500 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.96 · Expires 2028-10-25 | Direct | 7,592 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 7,592 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.41 · Expires 2029-10-24 | Direct | 8,044 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 8,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.92 · Expires 2030-10-29 | Direct | 6,028 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 6,028 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.81 · Expires 2031-10-28 | Direct | 2,532 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 2,532 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.94 · Expires 2032-10-27 | Direct | 3,460 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 3,460 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.51 · Expires 2033-10-26 | Direct | 3,937 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 3,937 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.37 · Expires 2034-10-24 | Direct | 3,511 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 3,511 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.96 · Expires 2035-10-30 | Direct | 3,777 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 3,777 F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
LIGAND PHARMACEUTICALS INC
Report date December 28, 2022 · Filed December 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 417,695 |
Reported balance
After 2022-12-28 transaction · row 1
1 source rowRow 1 · 2022-12-28 · Tax withholding · Disposed 5,289 · Balance 417,695 |
OmniAb, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,962,320 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Exercise / conversion · Acquired 20,000 · Balance 2,962,320 F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Exercise / conversion · Disposed 20,000 · Balance 0 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2026-06-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-17 · Grant · Acquired 20,000 · Balance 20,000 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.03 · Expires 2036-06-17 | Direct | 40,000 |
Reported balance
After 2026-06-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-17 · Grant · Acquired 40,000 · Balance 40,000 F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2019 Filed Jan 25, 2019 21:31 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 7,256 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000017 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,465 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 02/11/2016 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2018. On January 23, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 14:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0000886163-19-000004 · edgardoc.xml · derivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2019-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 2/15/09. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 14:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 29,790 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0000886163-19-000004 · edgardoc.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,790 shares Expires 2019-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 2/15/09. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 14:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 29,790 | $16.14 | $480,810.60 |
DisclosureSEC source: 0000886163-19-000004 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 14:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 4,000 | $16.14 | $64,560.00 |
DisclosureSEC source: 0000886163-19-000004 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 20:54 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 1,898 | $0.00 Strike: $179.84 | $0.00 |
DisclosureSEC source: 0001562180-18-004304 · primarydocument.xml · derivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 Underlying: Common Stock · 1,898 shares Expires 2028-10-25 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/25/2019) or the date of Bio-Techne 2019 Annual Meeting of Shareholders. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 20:54 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004304 · primarydocument.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,526 Read SEC document |
| August 30, 2018 Filed Aug 31, 2018 17:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,500 | $258.25 | $903,875.00 |
DisclosureSEC source: 0000886163-18-000127 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,419 Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 20:12 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $61.08 | $0.00 |
DisclosureSEC source: 0000914190-18-000352 · edgar.xml · derivative · entry 12 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 20:12 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 10,000 | $187.92 | $1,879,173.00 |
DisclosureSEC source: 0000914190-18-000352 · edgar.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,012 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $187.60 to $188.22 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 20:12 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 10,000 | $61.08 | $610,800.00 |
DisclosureSEC source: 0000914190-18-000352 · edgar.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2018 Filed Aug 17, 2018 23:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,993 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000886163-18-000121 · edgardoc.xml · derivative · entry 6 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,000 Underlying: Common Stock · 12,993 shares Expires 2022-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on June 22, 2018, in accordance with Rule 10b5-1. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/09/12. Read SEC document |
| August 17, 2018 Filed Aug 17, 2018 23:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 12,993 | $243.00 | $3,157,299.00 |
DisclosureSEC source: 0000886163-18-000121 · edgardoc.xml · nonDerivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,919 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on June 22, 2018, in accordance with Rule 10b5-1. Read SEC document |
| August 17, 2018 Filed Aug 17, 2018 23:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 12,993 | $14.47 | $188,008.71 |
DisclosureSEC source: 0000886163-18-000121 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on June 22, 2018, in accordance with Rule 10b5-1. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 23:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,007 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000886163-18-000121 · edgardoc.xml · derivative · entry 5 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,993 Underlying: Common Stock · 3,007 shares Expires 2022-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on June 22, 2018, in accordance with Rule 10b5-1. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/09/12. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 23:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 21,507 | $241.33 | $5,190,260.65 |
DisclosureSEC source: 0000886163-18-000121 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,919 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on June 22, 2018, in accordance with Rule 10b5-1. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 23:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 3,007 | $14.47 | $43,511.29 |
DisclosureSEC source: 0000886163-18-000121 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on June 22, 2018, in accordance with Rule 10b5-1. Read SEC document |
| May 15, 2018 Filed May 15, 2018 22:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 12,405 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0000886163-18-000069 · edgardoc.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,790 Underlying: Common Stock · 12,405 shares Expires 2019-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 20, 2017, in accordance with Rule 10b5-1. F3 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 2/15/09. Read SEC document |
| May 15, 2018 Filed May 15, 2018 22:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 12,405 | $179.97 | $2,232,490.64 |
DisclosureSEC source: 0000886163-18-000069 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,419 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 20, 2017, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.34 to $180.82, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2018 Filed May 15, 2018 22:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 12,405 | $16.14 | $200,216.70 |
DisclosureSEC source: 0000886163-18-000069 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 20, 2017, in accordance with Rule 10b5-1. Read SEC document |
| March 06, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,982 | $165.87 | $494,624.34 |
DisclosureSEC source: 0000886163-18-000040 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,419 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| March 06, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 6,015 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-18-000040 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,401 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer?s common stock. The PSUs were originally granted on 02/11/2016 and were eligible to vest based on the Issuer?s achievement of certain performance objectives during the two-year performance period ending December 31, 2017. On March 05, 2018, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer?s achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 41,392 | $0.00 Strike: $159.01 | $0.00 |
DisclosureSEC source: 0000886163-18-000040 · edgardoc.xml · derivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,392 Underlying: Common Stock · 41,392 shares Expires 2028-03-02 F3 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 03/02/18. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 7,928 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-18-000040 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,386 Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:38 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,689 | $157.18 | $265,477.02 |
DisclosureSEC source: 0000886163-18-000017 · edgardoc.xml · nonDerivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,458 F5 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/24/2017. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:38 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,918 | $157.18 | $301,471.24 |
DisclosureSEC source: 0000886163-18-000017 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,147 F4 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2016. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:38 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,635 | $157.18 | $414,169.30 |
DisclosureSEC source: 0000886163-18-000017 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,065 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/10/2015. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:38 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 9,000 | $157.03 | $1,413,279.00 |
DisclosureSEC source: 0000886163-18-000017 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,700 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 20, 2017, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.09 to $158.88, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 22:31 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 22,500 | $165.00 | $3,712,500.00 |
DisclosureSEC source: 0000886163-18-000009 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,700 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 20, 2017, in accordance with Rule 10b5-1. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 00:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 16,249 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0000886163-18-000007 · edgardoc.xml · derivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,195 Underlying: Common Stock · 16,249 shares Expires 2019-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 20, 2017, in accordance with Rule 10b5-1. F3 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 2/15/09. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 00:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 11,850 | $151.92 | $1,800,306.51 |
DisclosureSEC source: 0000886163-18-000007 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,200 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 20, 2017, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.81 to $152.24, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 00:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 16,249 | $155.00 | $2,518,595.00 |
DisclosureSEC source: 0000886163-18-000007 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,050 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 20, 2017, in accordance with Rule 10b5-1. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 00:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 16,249 | $16.14 | $262,258.86 |
DisclosureSEC source: 0000886163-18-000007 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 20, 2017, in accordance with Rule 10b5-1. Read SEC document |
| December 28, 2017 Filed Dec 30, 2017 02:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 5,199 | $138.66 | $720,893.34 |
DisclosureSEC source: 0000886163-17-000158 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,050 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| December 28, 2017 Filed Dec 30, 2017 02:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 9,965 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000158 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,249 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer?s common stock. The PSUs were originally granted on 02/10/2015 and were eligible to vest based on the Issuer?s achievement of certain performance objectives during the three-year performance period ending December 31, 2017. On December 28, 2017, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer?s achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 22:01 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,258 | $140.34 | $316,887.72 |
DisclosureSEC source: 0000886163-17-000143 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,284 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.29 to $140.37, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 22:10 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 5,269 | $142.53 | $750,990.57 |
DisclosureSEC source: 0000886163-17-000136 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,542 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.00 to $143.50, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:54 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003377 · primarydocument.xml · derivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2027-10-27 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/18) or the date of Bio-Techne's 2018 annual meeting of shareholders. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:54 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003377 · primarydocument.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,012 Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 21:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 11,384 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0000886163-17-000119 · edgardoc.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,384 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/15/13. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 21:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,744 | $143.04 | $249,461.76 |
DisclosureSEC source: 0000886163-17-000119 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,811 F1 · shares: Represents previously-owned shares delivered to the Issuer in payment of the exercise price of the stock options. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 21:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 11,384 | $21.92 | $249,537.28 |
DisclosureSEC source: 0000886163-17-000119 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 00:48 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000112 · edgardoc.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 2/23/08. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 00:48 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 5,000 | $130.00 | $650,000.00 |
DisclosureSEC source: 0000886163-17-000112 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,171 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on May 11, 2017, in accordance with Rule 10b5-1. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 00:48 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 5,000 | $21.00 | $105,000.00 |
DisclosureSEC source: 0000886163-17-000112 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on May 11, 2017, in accordance with Rule 10b5-1. Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 22:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 5,483 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000097 · edgardoc.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,483 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on May 11, 2017, in accordance with Rule 10b5-1. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 2/23/08. Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 22:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 5,483 | $125.00 | $685,375.00 |
DisclosureSEC source: 0000886163-17-000097 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,171 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on May 11, 2017, in accordance with Rule 10b5-1. Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 22:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 5,483 | $21.00 | $115,143.00 |
DisclosureSEC source: 0000886163-17-000097 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on May 11, 2017, in accordance with Rule 10b5-1. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,666 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000081 · edgardoc.xml · derivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,666 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on May 11, 2017, in accordance with Rule 10b5-1. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 4,666 | $120.00 | $559,920.00 |
DisclosureSEC source: 0000886163-17-000081 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,171 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on May 11, 2017, in accordance with Rule 10b5-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.